CareDx Hosting Pan-Organ Symposium, "Elevating Transplant Care by Combining Molecular Diagnostics and Artificial Intelligence"
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it is showcasing the clinical value of multimodality and artificial intelligence innovation at the annual American Society of Transplantation Cutting Edge of Transplantation (CEoT) meeting taking place February 23-25, in Scottsdale, Arizona.
"We are excited to be part of this year's CEoT meeting which brings together world-class leaders who are collectively challenging the status quo by driving innovation and new frontiers in transplantation," said Reg Seeto, CEO and President of CareDx. "I am extremely proud of the progress CareDx has made in bolstering these efforts by providing innovative, multimodal and artificial intelligence-enabled solutions that are poised to make a seminal difference in improving patients' long-term allograft health."
CareDx has assembled leading experts who will discuss the latest scientific advancements in kidney, heart, and lung transplantation. The symposium, "Elevating Transplant Care by Combining Molecular Diagnostics and Artificial Intelligence," will be held on Friday, February 24, from 7:00 am – 8:15 am. Speakers include:
- Sanjiv Anand, MD, MS, Medical Director, Living Donor Kidney Program, Intermountain Medical Center
- Enver Akalin, MD, FAST, FASN, Medical Director, Kidney and Pancreas Transplantation, Montefiore Medical Center; Director, Transplant Nephrology Fellowship, Professor of Medicine, Albert Einstein College of Medicine
- Titte "Srini" Srinivas, MD, MBA, FAST, Senior Vice President, Medical Affairs and Clinical Operations, CareDx
- Nikhil Agrawal, MD, Senior Medical Director, CareDx
- Sean Pinney, MD, Professor of Medicine; Co-Director, Heart and Vascular Center; Director, Richard P. Parrillo Family Center for Clinical and Translational Cardiology; Director, Advanced Heart Failure, Transplant and Mechanical Circulatory Support, University of Chicago Medicine
- Howard Huang, MD, Transplant Pulmonologist and Lung Transplantation Section Chief, Houston Methodist J.C. Walter Jr. Transplant Center
- Jeremy Kobulnik, MD, MHSc, Medical Director, CareDx
"This year's CEoT meeting theme, 'embracing new frontiers in transplantation' is fortuitous given the recent addition of dd-cfDNA in the ISHLT (International Society for Heart and Lung Transplantation) guidelines. Molecular surveillance is gaining momentum and I am proud to be part of the American Society of Transplantation committee that wrote a letter to the Centers for Medicare & Medicaid Services advocating for continued advancement of biomarker research in organ transplantation," said Sean Pinney, MD, Professor of Medicine; Co-Director, Heart and Vascular Center; Director, Richard P. Parrillo Family Center for Clinical and Translational Cardiology; Director, Advanced Heart Failure, Transplant and Mechanical Circulatory Support, University of Chicago Medicine. "Molecular biomarkers are increasingly being considered as an effective non-invasive alternative to biopsy that can help clinicians assess allograft function and rejection."
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx's leading participation in the CEoT meeting (the "CEoT Participation"). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its CEoT Participation; risks that the CEoT meeting, including the symposium and speeches assembled by CareDx, fails to take place on time, invite the speakers, or discuss the topics as stated in this press release; general economic and market factors; and other risks discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the quarter ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022, the quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed by CareDx with the SEC on August 4, 2022, the quarterly report on Form 10-Q for the quarter ended September 30, 2022 filed by CareDx with the SEC on November 3, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.